Changes of Tear-film Lipid Layer Thickness and Ocular Aberration After Treatment of Meibomian Gland Dysfunction

Study Overview
=================
Brief Summary
-----------------
In this study, investigator aim to evaluate the changes of tear-film lipid layer thickness and ocular aberration after treatment of meibomian gland dysfunction. In case of stage 3 or 4 meibomian gland dysfunction, participants will be treated using conventional treatment modalities. Before treatment and after 1 and 2 months of treatment, a variety of ophthalmic examination, tear-film lipid layer thickness, and ocular aberration are going to measured and compared.

Conditions
-----------------
Meibomian Gland Dysfunction

Intervention / Treatment
-----------------
* Drug: Treatment of Meibomian gland dysfunction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. age over 19 years old, with moderate to severe Meibomian gland dysfunction. Exclusion Criteria: patients with history of previous ocular or intraocular surgery ocular infection, non dry eye ocular inflammation, ocular allergy, autoimmune disease history of intolerance or hypersensitivity to any component of the study medications wearing contact lenses during the study period, presence of current punctal occlusion pregnancy, lactating women, and children

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: moderate to severe meibomian gland dysfunction<br> | Drug: Treatment of Meibomian gland dysfunction<br>* artificial tears, 3% Diquafosol Tetrasodium eye drops, steroid eye drops, squeezing of meibomian glands, cleansing of eyelids.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes of tear-film lipid layer thickness after treatment of meibomian gland dysfunction |  | 1 and 2 months after treatment of meibomian gland dysfunction | 
| Changes of ocular aberration after treatment of meibomian gland dysfunction | ocular parameters measured by Ray-tracing wavefront aberrometers (i-Trace, Tracey technologies , Texas ,USA) | 1 and 2 months after treatment of meibomian gland dysfunction | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Corneal erosion grade(oxford score) |  | 1 and 2 months after treatment of meibomian gland dysfunction | 
| OSDI(ocular surface disease index) |  | 1 and 2 months after treatment of meibomian gland dysfunction | 
| Meibomian gland abnormality | measured by physiological parameter (score 0,1,2,3,4) | 1 and 2 months after treatment of meibomian gland dysfunction | 
| Meibomian quality | measured by physiological parameter (score 0,1,2,3,4) | 1 and 2 months after treatment of meibomian gland dysfunction | 
| BUT(tear break-up time) |  | 1 and 2 months after treatment of meibomian gland dysfunction | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Meibomian gland dysfunction, Lipiview, Tear Lipid Layer